NAB – The Morning Call · Astra Zeneca re-run, Lane’s credit concerns
0
AUDIO The Morning Call

Astra Zeneca re-run, Lane’s credit concerns

By phildobbie — 2 months ago

Friday 27th November 2020

There are some questions over the numbers provided in phase three of the Astra Zeneca vaccine trial. NAB’s David de Garis says the concern is over the age of participations in the subset who achieved the highest level of efficiency. The makers claim a rerun of trials won’t slow progress, although some believe it could delay entry into the US. The ECB’s Philip Lane expressed concern about tightened of credit standards which could impede the European recovery. Meanwhile, lockdowns are being extended in parts of Europe. And on a quiet day in the markets, the pound is lower, with another day passing without any Brexit progress.

Post Views: 159

Leave a Reply

Your email address will not be published. Required fields are marked *

THE TWITTERATI

Phil DobbieFollow

Phil Dobbie
phildobbiePhil Dobbie@phildobbie·
8h

Don't expect too much from the Fed meeting later today. NAB's Tapas Strickland on the morning call. Full podcast here: https://t.co/cxAjYkDmBG

Reply on TwitterRetweet on TwitterLike on TwitterTwitter
phildobbiePhil Dobbie@phildobbie·
9h

With central banks colluding with governments to coordinate fiscal and monetary policy, on today's #DebunkingEconomics podcast, I ask @profstevekeen is their independence a thing of the past? https://t.co/pe31YygYTn

Reply on TwitterRetweet on Twitter3Like on Twitter12Twitter
Load More...
Scroll to top